Akari Therapeutics plc ADS (NASDAQ: AKTX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AKARI THERAPEUTICS PLC ADS

Akari Therapeutics plc ADS (NASDAQ: AKTX)
Listen to this Section


$9.92
-0.8100 ( -7.55% ) 0.0K

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Clinical Trial Pipeline Stages


Drug Name Stage
NomacopanDetailsParoxysmal nocturnal hemoglobinuria Phase 3
NomacopanDetailsHematopoietic stem cell transplantation thrombotic microangiopathies Phase 3
NomacopanDetailsCOVID-19 Phase 2
NomacopanDetailsAtopic Keratoconjunctivitis Phase 1/2
NomacopanDetailsGeographic atrophy, Eye disease Phase 1
NomacopanDetailsBullous pemphigoid Failed

Market Data


Open $9.92
Previous Close $10.73
Volume 0.0K
Market Cap $16.89M
Day Range $12.10 - $12.10
52 Week Range $3.02 - $49.60
Shares Outstanding 1.57M
Change % -7.55%
Net Change ▼ -0.8100
Insider Ownership N/A
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2012
CountryUnited Kingdom

Insider Ownership Transactions

Total Amount Purchased: -3,404,356,151.00

Date Type Amount Purchased Purchaser
2026-03-16 Buy 2473.00 Neal James R
2025-12-18 Buy 247462.00 Patel Sandip I
2025-12-18 Buy 309328.00 Gaslightwala Abizer
2025-12-18 Buy 123731.00 Bazemore Robert B
2025-12-18 Buy 618658.00 Huh Hoyoung
2025-12-18 Buy 618658.00 Prudo-Chlebosz Raymond
2025-12-18 Buy 618658.00 Patel Samir Rashmikant
2025-12-18 Buy 24745.00 Farag Kameel D.
2025-08-29 Buy 10000.00 Gaslightwala Abizer
2025-06-25 Buy 943.00 Gaslightwala Abizer

SEC Filings


Form Type Description Pages Date
10-k Annual reports 95 Mar 30, 2026
8-k 8K-related 14 Mar 17, 2026
4 Insider transactions 2 Mar 16, 2026
schedule Other 1 Mar 04, 2026
schedule Other 1 Mar 04, 2026
schedule Other 1 Mar 04, 2026
8-k 8K-related 14 Mar 02, 2026
def Proxies and info statements 5 Feb 02, 2026
s-1 Registration statements 129 Jan 23, 2026
pre Proxies and info statements 5 Jan 22, 2026

Latest News